- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Review, Journal: Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. (Pubmed Central) - Mar 12, 2024
PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted.
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Comprehensive characterization of polyproline tri-helix macrocyclic nanoscaffolds for predictive ligand positioning. (Pubmed Central) - Feb 1, 2024
The present work enhances the precision of nanoscale organic synthesis, offering prospects for controlled ligand positioning on scaffolds. This advancement paves the way for further applications in nanomedicine through selective protein interaction, manipulation of cell surface receptor functions, and developments of more complex polyproline-based nanostructures.
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. (Pubmed Central) - Jan 23, 2024
An observational, prospective, one-year follow-up study was carried out with patients (N = 68) with severe schizophrenia treated with paliperidone three-month (PP3M) or aripiprazole one-month (ARIM)...Considering the non-linear dose-PL relationship of ARIM and PP3M in people with severe schizophrenia, PLs above the TRR are linked to better treatment outcomes, without worse tolerability. The need in a notable number of cases for high doses to reach those effective PLs is highlighted.
- |||||||||| clozapine / Generic mfg.
Review, Journal: Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review. (Pubmed Central) - Nov 22, 2023
This preliminary evidence suggests clinical utility of LAIs in alleviating residual symptoms and subsequently reducing hospitalisation rates in patients optimised on clozapine treatment. The current study warrants further investigations including a randomised controlled study to establish the clinical efficacy, tolerability, and place in therapy of this treatment modality.
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, Adherence: Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety. (Pubmed Central) - Oct 11, 2023
Hospital admissions decreased significantly in those patients with high PLs. Taking into account the absence of a linear relationship between doses and PLs, the effectiveness in people with severe schizophrenia of AOM and PP3M depends on reaching high PLs, achieved with high doses, but also with standard doses in some cases, without leading to worse treatment tolerability, safety, or adherence.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, HEOR: Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. (Pubmed Central) - Aug 21, 2023
The probability sensitivity analysis (PSA) revealed that when the WTP thresholds were $12,756.55/QALY, the probability of PP1M and PP3M being cost-effective was 59.2% and 66.0%, respectively. From the Chinese healthcare system perspective, PP3M and PP1M are both more cost-effective compared to ER, and PP3M has notable cost-utility advantages over PP1M.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. (Pubmed Central) - Aug 7, 2023
For patients with schizophrenia stabilized with paliperidone ER, switching to LAI formulations was not cost-effective, suggesting the high drug costs for LAI may not justify the improved quality of life within 5 years. Among LAI formulations, PP6M was cost-effective over PP1M and PP3M.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety. (Pubmed Central) - Jul 19, 2023
This descriptive, cross-sectional survey explored patient's satisfaction and perspectives on the advantages and disadvantages of switching from monthly to 3-monthly paliperidone while also reporting on perceived levels of safety with regard to the reducing dose regimen during the Covid-19 pandemic...In fact, only one patient discontinued PP3M at one year with the overall number of hospitalisations also reducing in the same period compared to the year before switching. Our findings add to the small, but growing, body of evidence supporting patient satisfaction and acceptance with the use of PP3M and may reinforce the use of less frequent LAIs in clinical practice to enhance individual experience and treatment persistence and decrease levels of stigmatisation.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Analyzing Demographic Variabilities Associated With Age of Diagnosis of Schizophrenia Among Patients in Controlled Clinical Trials (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_973;
Our analysis differs from previous studies and finds that AOD for male and female patients are seen in a unimodal distribution as compared to previous literature that shows a bimodal and trimodal distribution. Our findings not only call for a re-evaluation of previous epidemiological understandings of AOD but may support future efforts in understanding the origins and typical clinical presentations of patients with newly developed symptomatology of schizophrenia as well as support clinicians
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
A Case Report of a Patient Who Required a Second Long-Acting Injectable Antipsychotic to Stabilize Him (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_650;
RB is a 37-year-old African American male, single, unemployed, domiciled in supportive housing, with past psychiatric history of Schizophrenia and Cannabis Use Disorder, multiple prior psychiatric hospitalizations, and a forensic history, who was followed by an Assertive Community Treatment team and receiving 3-monthly Paliperidone Palmitate 819 mg (last given 3-4 weeks prior to presentation) and oral Risperidone...Risperidone was discontinued and Fluphenazine 5 mg twice daily was started...Currently treatment guidelines do not support antipsychotic polypharmacy regardless of the formulation of the regimen or address two or more LAIs for treatment of Schizophrenia. Our case offers an alternative on how to manage patients with breakthrough symptoms and simultaneously address issues of treatment non-adherence in the community.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. (Pubmed Central) - May 16, 2023
We estimated an overall improvement over time on the explored outcomes, without differences with respect to the type of LAI investigated, and with a global 16.4% dropout rate. Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen.
- |||||||||| Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
Review, Journal: The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. (Pubmed Central) - Mar 15, 2023
By eliminating the need for daily oral antipsychotic dosing, LAIs could increase the likelihood of patient acceptance, decrease stigma, and promote self-esteem. Longer intervals of medication coverage may be desirable for patients with higher risk of relapse including adults with recent-onset schizophrenia, those living in circumstances that may deprive them of regular access (eg, homeless), those that are in transitions between care settings or to reduce interpersonal contact during public health emergencies (eg, COVID-19 pandemic).
- |||||||||| Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label Extension of a Double-Blind Study in Adult Patients with Schizophrenia () - Mar 10, 2023 - Abstract #SIRS2023SIR_770;
P3
Longer intervals of medication coverage may be desirable for patients with higher risk of relapse including adults with recent-onset schizophrenia, those living in circumstances that may deprive them of regular access (eg, homeless), those that are in transitions between care settings or to reduce interpersonal contact during public health emergencies (eg, COVID-19 pandemic). No deaths were reported during this study.Discussion The relapse rate with LAI PP6M, administered twice-yearly, was very low (<4%).Clinical improvements in PANSS, CGI-S, and PSP scales demonstrated in the DB study weremaintained during this 2-year OLE study and no new safety concerns were identified.KeywordKeywordsLong-acting injectablePaliperidone palmitate 6-monthPaliperidone palmitate 3-monthSchizophreniaRelapsePoster Award NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationDean Najarian Janssen Scientific Affairs, LLC,Titusville, NJ, USAIbrahim Turkoz Janssen Research & Development,LLC, Titusville, NJ, USASilvana Galderisi University of Campania
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, HEOR: Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. (Pubmed Central) - Mar 2, 2023
Aditya Raju was an employee of Xcenda at the time of the development and finalization of the manuscript, and Danmeng Huang is an employee of Xcenda, a health care consulting firm that was contracted by Janssen Scientific Affairs, LLC. Chih-Yuan Cheng is an employee of Janssen NV.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed: CASPAR: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (clinicaltrials.gov) - Mar 2, 2023
P4, N=93, Active, not recruiting,
Clinical improvements in PANSS, CGI-S, and PSP scales demonstrated in DB study were maintained during this 2-year OLE study and no new safety concerns were identified. Recruiting --> Active, not recruiting
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia. (Pubmed Central) - Jan 27, 2023
Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social performance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social functioning of and promote return to activities of daily living in patients with schizophrenia.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation. (Pubmed Central) - Nov 22, 2022
Increased psychopathology severity was associated with an increased likelihood of relapse, while having a job or being in school was protective. These findings reinforce the necessity of conducting research in patients with comorbid psychiatric disorders who are typically underrepresented in RCTs, yet overrepresented in real-life settings, in order to better inform and guide clinical practice.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, HEOR: Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. (Pubmed Central) - Nov 16, 2022
Ms Morrison, Ms Ghelerter, Ms Vermette-Laforme, Mr Lefebvre, and Mr Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC., which funded the development and conduct of this study and manuscript. Dr Lin and Ms Benson are employees of Janssen Scientific Affairs, LLC., and stockholders of Johnson & Johnson.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Reimbursement, Retrospective data, Journal, Real-world evidence, Medicaid: Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. (Pubmed Central) - Nov 10, 2022
Dr Lin and Ms Benson are employees of Janssen Scientific Affairs, LLC., and stockholders of Johnson & Johnson. This real-world investigation of adult Medicaid members with schizophrenia or schizoaffective disorder observed improved adherence and persistence with fewer readmissions with PP1M/PP3Ms versus OAP-switches.
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance. (Pubmed Central) - Oct 26, 2022
This real-world investigation of adult Medicaid members with schizophrenia or schizoaffective disorder observed improved adherence and persistence with fewer readmissions with PP1M/PP3Ms versus OAP-switches. Our study suggests that switching from risperidone to PP in patients with schizophrenia is associated with an improvement in social functioning and cognitive performance.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Alternative initiations of 3-monthly paliperidone palmitate. A retrospective study (Poster area [ONLINE]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1237;
In this descriptive study we present a sample of patients with severe mental disorder with a complex course who responded excellently to 3-monthly paliperidone palmitate directly with oral supplementation for 45 days or with an initial dose of paliperidone palmitate monthly followed by direct maintenance with 3-monthly paliperidone palmitate, without the need for a 4-month wait with the monthly paliperidone palmitate regimen. This reduction in time to reach the 3-monthly LAIA regimen could be related to the excellent efficacy, tolerability and adherence observed in the present study.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
First clinical experiences with 6-monthly paliperidone palmitate – A retrospective study (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1030;
In the present study, the use of said LAIA in a group of 20 patients is objectified, showing excellent efficacy and tolerability. All study patients were already stable with the 1-monthly and 3-monthly paliperidone palmitate formulations, maintaining said psychopathological stability when switching to the 6-monthly paliperidone palmitate formulation, with excellent adherence and adverse effect profile .
- |||||||||| aripiprazole / Generic mfg.
Depot aripiprazole versus paliperidone in dual disorder patients – an observational study (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_942;
We compared three treatment lines: monthly aripiprazole, monthly paliperidone and three month paliperidone. Methods : We conducted an open observational study with a sample of 265 patients from A Coruña (Spain)...We observe also that paliperidone was often used in more severe patients..Side effects were observed more often with paliperidone, but the number of them was relatively low with both treatment lines. We also observed that the abstinence rate was about 80% and adherence rates overcame 90%, indicating that the greatest part of the patients observed at least some grade of improvement that made them stay in the program.In Conclusion , both drugs seemed to be effective on treating dual disorder patients, with a more favourable side effect profile for aripiprazole.
|
